Index of artpub/2022/pmc_9588896/

Le Tourneau, C
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
2022
https://ddd.uab.cat/record/283621